Combination

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
BACKGROUND: The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic …
Mikkel Østergaard, Ronald F. van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C. Nordström, Michael T. Nurmohamed, Bjorn Gudbjornsson, Lykke Midtbøll Ørnbjerg, Pernille Bøyesen, Kristina Lend, Kim Hørslev-Petersen, Till Uhlig, Tuulikki Sokka, Gerdur Grondal, Simon Krabbe, Joakim Lindqvist, Inger Gjertsson, Daniel Glinatsi, Meliha Crnkic Kapetanovic, Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, Tove Lorenzen, Cagnotto Giovanni, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Maud Kristine Ljoså, Eli Brodin, Hanne Lindegaard, Annika Söderbergh, Milad Rizk, Alf Kastbom, Per Larsson, Line Uhrenholt, Søren Andreas Just, David J. Stevens, Trine Bay Laurbjerg, Gunnstein Bakland, Inge Christoffer Olsen, Espen A. Haavardsholm, Jon Lampa, NORD-STAR study group
Cite DOI
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
Importance: Sustained remission has become an achievable goal for patients with rheumatoid arthritis (RA) receiving conventional …
Siri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge C. Olsen, Hallvard Fremstad, Cristina Spada, Tor Magne Madland, Christian A. Høili, Gunnstein Bakland, Åse Lexberg, Inger Johanne Widding Hansen, Inger Myrnes Hansen, Hilde Haukeland, Maud-Kristine Aga Ljoså, Ellen Moholt, Till Uhlig, Daniel H. Solomon, Désirée van der Heijde, Tore K. Kvien, Espen A. Haavardsholm
Cite DOI
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial
OBJECTIVE: To evaluate and compare benefits and harms of three biological treatments with different modes of action versus active …
Merete Lund Hetland, Espen A. Haavardsholm, Anna Rudin, Dan Nordström, Michael Nurmohamed, Bjorn Gudbjornsson, Jon Lampa, Kim Hørslev-Petersen, Till Uhlig, Gerdur Grondal, Mikkel Østergaard, Marte S. Heiberg, Jos Twisk, Kristina Lend, Simon Krabbe, Lise Hejl Hyldstrup, Joakim Lindqvist, Anna-Karin Hultgård Ekwall, Kathrine Lederballe Grøn, Meliha Kapetanovic, Francesca Faustini, Riitta Tuompo, Tove Lorenzen, Giovanni Cagnotto, Eva Baecklund, Oliver Hendricks, Daisy Vedder, Tuulikki Sokka-Isler, Tomas Husmark, Maud-Kristine Aga Ljoså, Eli Brodin, Torkell Ellingsen, Annika Söderbergh, Milad Rizk, Åsa Reckner Olsson, Per Larsson, Line Uhrenholt, Søren Andreas Just, David John Stevens, Trine Bay Laurberg, Gunnstein Bakland, Inge C. Olsen, Ronald van Vollenhoven, NORD-STAR study group
Cite DOI
Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry
OBJECTIVE: To describe the outcomes of MTX and biologic DMARD (bDMARD) treatment in patients with RA and assess unmet needs in patients …
Inge C. Olsen, Elisabeth Lie, Radu Vasilescu, Gene Wallenstein, Sander Strengholt, Tore K. Kvien
Cite DOI
ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial
OBJECTIVE: To investigate whether ω-3 fatty acids reduce magnetic resonance imaging (MRI) and clinical disease activity in patients …
Oivind Torkildsen, Stig Wergeland, Søren Bakke, Antonie G. Beiske, Kristian S. Bjerve, Harald Hovdal, Rune Midgard, Finn Lilleås, Tom Pedersen, Bård Bjørnarå, Frøydis Dalene, Grethe Kleveland, Jan Schepel, Inge Christoffer Olsen, Kjell-Morten Myhr
Cite DOI
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
BACKGROUND: Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective, and new more effective …
Per Soelberg Sorensen, Svein Ivar Mellgren, Anders Svenningsson, Irina Elovaara, Jette Lautrup Frederiksen, Antonie Giaever Beiske, Kjell-Morten Myhr, Lise Vejby Søgaard, Inge Christoffer Olsen, Magnhild Sandberg-Wollheim
Cite DOI